Literature DB >> 21087406

A longitudinal assessment of painful diabetic peripheral neuropathy on health status, productivity, and health care utilization and cost.

Marco daCosta DiBonaventura1, Joseph C Cappelleri, Ashish V Joshi.   

Abstract

OBJECTIVE: The aim of the current study was to examine the health outcomes of patients suffering from painful diabetic peripheral neuropathy (pDPN) over a 3-year period, relative to patients with diabetes but without neuropathic pain and controls.
DESIGN: The current study included participants who completed three consecutive waves of the National Health and Wellness Survey (2006-2008). These participants were categorized into one of three groups: those with pDPN (N=290), those with diabetes but without pDPN ("diabetes without pDPN group"; N=1,037), and those not diagnosed with diabetes ("control group"; N=8,162). OUTCOME MEASURES: Health status (Short Form-12v2), work productivity (Work Productivity and Activity Impairment Questionnaire), and resource use were examined with repeated-measures models adjusting for demographic and clinical factors.
RESULTS: The pDPN group reported significantly lower levels of physical quality of life. Moreover, physical quality of life scores for the pDPN group decreased at a significantly faster rate over a 3-year period relative to other groups. In addition, the pDPN patients reported significantly higher levels of impairment of work productivity and activity, greater resource use, and higher total 3-year per-patient costs.
CONCLUSIONS: Confirming and expanding upon the literature, our results indicate a significantly worse trajectory of quality of life outcomes over time and long-term increased total costs for pDPN patients relative to non-pDPN diabetes patients and controls. Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2010        PMID: 21087406     DOI: 10.1111/j.1526-4637.2010.01012.x

Source DB:  PubMed          Journal:  Pain Med        ISSN: 1526-2375            Impact factor:   3.750


  33 in total

1.  Efficacy of Inhaled Cannabis on Painful Diabetic Neuropathy.

Authors:  Mark S Wallace; Thomas D Marcotte; Anya Umlauf; Ben Gouaux; Joseph H Atkinson
Journal:  J Pain       Date:  2015-04-03       Impact factor: 5.820

Review 2.  Physiological and psychological challenges of increasing physical activity and exercise in patients at risk of diabetic foot ulcers: a critical review.

Authors:  Ryan T Crews; Kristin L Schneider; Sai V Yalla; Neil D Reeves; Loretta Vileikyte
Journal:  Diabetes Metab Res Rev       Date:  2016-06-10       Impact factor: 4.876

3.  Reducing CXCR4-mediated nociceptor hyperexcitability reverses painful diabetic neuropathy.

Authors:  Nirupa D Jayaraj; Bula J Bhattacharyya; Abdelhak A Belmadani; Dongjun Ren; Craig A Rathwell; Sandra Hackelberg; Brittany E Hopkins; Herschel R Gupta; Richard J Miller; Daniela M Menichella
Journal:  J Clin Invest       Date:  2018-04-23       Impact factor: 14.808

4.  The effect of exercise on neuropathic symptoms, nerve function, and cutaneous innervation in people with diabetic peripheral neuropathy.

Authors:  Patricia M Kluding; Mamatha Pasnoor; Rupali Singh; Stephen Jernigan; Kevin Farmer; Jason Rucker; Neena K Sharma; Douglas E Wright
Journal:  J Diabetes Complications       Date:  2012-06-18       Impact factor: 2.852

5.  Burden of Illness of Diabetic Peripheral Neuropathic Pain: A Qualitative Study.

Authors:  Meryl Brod; Betsy Pohlman; Steven I Blum; Abhilasha Ramasamy; Robyn Carson
Journal:  Patient       Date:  2015-08       Impact factor: 3.883

6.  fMRI evidence of degeneration-induced neuropathic pain in diabetes: enhanced limbic and striatal activations.

Authors:  Ming-Tsung Tseng; Ming-Chang Chiang; Chi-Chao Chao; Wen-Yih I Tseng; Sung-Tsang Hsieh
Journal:  Hum Brain Mapp       Date:  2012-04-21       Impact factor: 5.038

7.  Pregabalin for Neuropathic Pain: Why Benefits Could Be Expected for Multiple Pain Conditions.

Authors:  Setsuro Ogawa; Akio Arakawa; Kazuhiro Hayakawa; Tamotsu Yoshiyama
Journal:  Clin Drug Investig       Date:  2016-11       Impact factor: 2.859

8.  Opioid utilization patterns among medicare patients with diabetic peripheral neuropathy.

Authors:  Jacqueline Pesa; Roxanne Meyer; Tiffany P Quock; Stacy K Rattana; Samir H Mody
Journal:  Am Health Drug Benefits       Date:  2013-05

9.  Anti-inflammatory mesenchymal stem cells (MSC2) attenuate symptoms of painful diabetic peripheral neuropathy.

Authors:  Ruth S Waterman; Jenny Morgenweck; Bobby D Nossaman; Anna E Scandurro; Sophia A Scandurro; Aline M Betancourt
Journal:  Stem Cells Transl Med       Date:  2012-07-09       Impact factor: 6.940

Review 10.  Burden of diabetes on the ability to work: a systematic review.

Authors:  Marie-Claude Breton; Line Guénette; Mohamed Amine Amiche; Jeanne-Françoise Kayibanda; Jean-Pierre Grégoire; Jocelyne Moisan
Journal:  Diabetes Care       Date:  2013-03       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.